Make your products visible globally with Elite Membership.
I agree to the terms and conditions
Existing User?
Sign In with Email
Remember Me Forgot Password?
New User?
Enter your registered Email ID to get reset password.
Elite Member
Individual Register
Lifitegrast is an FDA approved drug indicated for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca.Lifitegrast inhibits an integrin, lymphocyte function-associated antigen 1 (LFA-1), from binding to intercellular adhesion molecule 1 (ICAM-1). This mechanism down-regulates inflammation mediated by T lymphocytes.
Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) analog that has been developed by Novo Nordisk for the treatment of type 2 diabetes.Victoza lowers blood sugar by stimulating the pancreas to secrete insulin, effectively helping the body use insulin more efficiently when blood sugar levels are elevated.
Lofepramine is a third generation tricyclic antidepressant which was introduced in 1983 for the treatment of depressive disorders. It is partially converted to its active metabolite desipramine in vivo. However, it is unlikely this property plays a substantial role in its overall effects as lofepramine exhibits lower toxicity and anticholinergic side effects relative to desipramine while retaining equivalent antidepressant efficacy.
Lomevactone is a psychostimulant and antidepressant drug which was synthesized and studied in the 1980s, but was never marketed.
Lopirazepam is a short-acting benzodiazepine analog of the pyridodiazepine type with anxiolytic and hypnotic properties. It has never been marketed.
Loreclezole is a sedative and an anticonvulsant which acts as a GABA agonist. It binds allosterically to the GABAA receptor. The binding site of loreclezole has been shown experimentally to be shared by valerenic acid, an extract of the root of the valerian plant.
Lortalamine is an antidepressant which was synthesized in the early 1980s. It acts as a potent and highly selective norepinephrine reuptake inhibitor. It was under development for clinical use but was shelved, likely due to the finding that it produced ocular toxicity in animals. It has been used to label the norepinephrine transporter in positron emission tomography studies.
Lumiracoxib is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug, manufactured by Novartis. It has several distinctive features. Its structure is different from that of other COX-2 inhibitors, such as celecoxib. It is an analogue of diclofenac, making it a member of the arylalkanoic acid class of NSAIDs. It binds to a different site on the COX-2 receptor than do other COX-2 inhibitors. It is the only acidic coxib and has the highest COX-2 selectivity of any NSAID. Since its original approval, lumiracoxib has been withdrawn from the market in several countries, mostly due to hepatotoxicity concerns. It has never been approved for use in the United States.
Mebendazole is a benzimidazole drug. It is used to treat infestations by worms including pinworms, roundworms, tapeworms, hookworms, and whipworms.
Mepiprazole is a minor tranquilizer with a phenylpiperazine structure used for the treatment of anxiety neuroses. It acts as a 5-HT2 and α1-adrenergic receptor antagonist, and has also been shown to inhibit the reuptake and induce the release of serotonin, dopamine, and norepinephrine to varying extents. Similarly to other phenylpiperazines like trazodone, nefazodone, and etoperidone, mepiprazole produces mCPP as an active metabolite.
Stay updated with the latest chemical industry trends and innovations.
Verification Code has been sent to
Please enter the Verification Code below to verify your Email Address.If you cannot see the email from "noreply@worldofchemicals.com" in your inbox,make sure to check your SPAM Folder